← Leaderboards
Kiran Musunuru
University Of Pennsylvania
$21,648,838
Attributed
$25,408,078
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13M · FY2010–25$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,964,152 · 11
By mechanism
U19$23,399,369 · 3
U01$6,886,793 · 1
R01$6,007,241 · 4
R35$5,665,416 · 1
R00$730,068 · 1
K99$275,265 · 1
Top collaborators
- William H. Peranteau5 shared
- Rebecca Clare Ahrens-Nicklas3 shared
- Tarjei Sigurd Mikkelsen2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Daniel James Rader$77,348,993
- Marjorie E Marenberg$791,966
- Sony Tuteja$695,196
- Marina Cuchel$7,792,390
- Sylvia Georgieva Stankov$136,572
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesVariantLiverGenome EditingSuccessHepatocytePhenotypePreventTherapeutic Genome EditingPreventionPharmaceutical PreparationsTechnologyCause Of DeathLeadMutationBaseAffectLinkCardiovascular DiseasesGenome Wide Association StudyMetabolicGene FunctionInsightLdl Cholesterol Lipoproteins
Grant awards (43)
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$5,059,052
U19 · FY2025 · NS
Personalized prime editing as a platform for hepatic inborn errors of metabolism$2,710,325
U01 · FY2025 · TR
LEAD PROJECT 1: PHENYLKETONURIA (PKU)$1,843,290
U19 · FY2025 · NS · contact PI
Personalized prime editing as a platform for hepatic inborn errors of metabolism$1,427,560
U01 · FY2025 · TR
Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases$1,000,000
U19 · FY2025 · NS
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$812,500
R35 · FY2025 · HL · contact PI
ADMINISTRATIVE CORE$164,091
U19 · FY2025 · NS · contact PI
Replication study of in vivo postnatal gene editing for metabolic liver disease in the nonhuman primate model$29,667
U19 · FY2025 · NS
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$5,051,652
U19 · FY2024 · NS
Personalized prime editing as a platform for hepatic inborn errors of metabolism$2,748,908
U01 · FY2024 · TR
LEAD PROJECT 1: PHENYLKETONURIA (PKU)$1,419,953
U19 · FY2024 · NS · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$796,250
R35 · FY2024 · HL · contact PI
ADMINISTRATIVE CORE$277,392
U19 · FY2024 · NS · contact PI
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$6,415,703
U19 · FY2023 · NS
ADMINISTRATIVE CORE$1,069,285
U19 · FY2023 · NS · contact PI
LEAD PROJECT 1: PHENYLKETONURIA (PKU)$1,069,284
U19 · FY2023 · NS · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$812,500
R35 · FY2023 · HL · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$812,500
R35 · FY2022 · HL · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$812,500
R35 · FY2021 · HL · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$810,833
R35 · FY2020 · HL · contact PI
Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing$808,333
R35 · FY2019 · HL · contact PI
Permanent alteration of PCSK9 in vivo genome editing$402,500
R01 · FY2018 · HL · contact PI
Stem Cells Models of Familial Combined Hypolipidemia$402,500
R01 · FY2018 · HL · contact PI
Functional studies of KLF-14, a putative master regulator of metabolism$362,250
R01 · FY2018 · DK · contact PI
Stem Cells Models of Familial Combined Hypolipidemia$402,500
R01 · FY2017 · HL · contact PI
Permanent alteration of PCSK9 in vivo genome editing$402,500
R01 · FY2017 · HL · contact PI
Functional studies of KLF-14, a putative master regulator of metabolism$362,250
R01 · FY2017 · DK · contact PI
Stem Cells Models of Familial Combined Hypolipidemia$401,458
R01 · FY2016 · HL · contact PI
Functional studies of KLF-14, a putative master regulator of metabolism$361,313
R01 · FY2016 · DK · contact PI
High-throughput screening and stem cell modeling of causal eQTL variants$341,461
R01 · FY2016 · GM · contact PI
Stem Cells Models of Familial Combined Hypolipidemia$1,624
R01 · FY2016 · HL · contact PI
Stem Cell Models of Familial Combined Hypolipidemia$412,084
R01 · FY2015 · HL · contact PI
Functional studies of KLF14, a putative master regulator of metabolism$380,250
R01 · FY2015 · DK · contact PI
High-throughput screening and stem cell modeling of causal eQTL variants$314,001
R01 · FY2015 · GM · contact PI
Stem Cell Models of Familial Combined Hypolipidemia$409,993
R01 · FY2014 · HL · contact PI
High-throughput screening and stem cell modeling of causal eQTL variants$307,219
R01 · FY2014 · GM · contact PI
Genetic and functional analyses of a novel locus associated with LDL-C and MI$244,020
R00 · FY2014 · HL · contact PI
Stem Cell Models of Familial Combined Hypolipidemia$418,869
R01 · FY2013 · HL · contact PI
High-throughput screening and stem cell modeling of causal eQTL variants$324,469
R01 · FY2013 · GM · contact PI
Genetic and functional analyses of a novel locus associated with LDL-C and MI$237,048
R00 · FY2013 · HL · contact PI
Genetic and functional analyses of a novel locus associated with LDL-C and MI$249,000
R00 · FY2012 · HL · contact PI
Genetic and functional analyses of a novel locus associated with LDL-C and MI$137,970
K99 · FY2011 · HL · contact PI
Genetic and functional analyses of a novel locus associated with LDL-C and MI$137,295
K99 · FY2010 · HL · contact PI